Jun 03 2026SCIENCE
Lilly Partners With Ascidian to Edit RNA for Kidney Disease Drugs
Lilly has secured exclusive rights to use Ascidian’s RNA exon‑editing platform for new kidney disease treatments. The system can fix faulty genes without permanently changing a patient’s DNA, offering an alternative to traditional CRISPR methods. The deal gives Ascidian up to $1. 9 billion, split
reading time less than a minute
